BGNE Stock Recent News
BGNE LATEST HEADLINES
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average.
BeiGene stock popped Wednesday after the company's leukemia treatment beat out a blockbuster drug from Johnson & Johnson. The post BeiGene Takes On Johnson & Johnson's Blockbuster Cancer Drug — And Wins appeared first on Investor's Business Daily.
Teradyne, BeiGene, Agnico Eagle Mines and On Holding have strong balance sheets. They seem strong enough to ward off bankruptcy risk in the short, medium and long term.
These articles are intended to provide readers with equity investment subjects [stocks, ETFs, REITs] which probably may experience rising market prices in next 3-5 months: Near-term expectations only. They are drawn from a 3,000+ equity population updated daily which infers “Institutional” [big$] investor coming-price expectations from recent-past volume block-trade orders facilitated by Market-Makers.
Considering the slowdown in the world's second-largest economy, it's probably the right time to think about some Chinese stocks to sell. China barely escaped contraction during the second quarter as consumer and manufacturing activity slowed down in the face of repeated lockdowns.
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BeiGene, Ltd. (BGNE) witnessed a jump in share price last session on above-average trading volume.
Regulators in China agreed to start the review process for one of its medicines.
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.